Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 14/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 14/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 13/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19326035 | 0.91 | GABRA1 (0.36) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19320827 | 0.88 | CYP3A4 (0.32) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL19140209 | 0.87 | OPRM1 (0.35) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19321081 | 0.85 | POLQ (0.35) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19321076 | 0.85 | CACNA1G (0.37) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19325959 | 0.84 | CACNA1G (0.38) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19321039 | 0.84 | CACNA1G (0.41) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19320957 | 0.84 | CACNA1G (0.47) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19325906 | 0.84 | POLQ (0.34) | CACNA1GCACNA1HCACNA1IGABRA1GABRA2 | |
| SCHEMBL19321089 | 0.84 | ACHE (0.39) | CACNA1GCACNA1HCACNA1IACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | CACNA1G 3034/4885CACNA1H 2888/4885CACNA1I 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.